Biohaven Readies Glutamate Modulator BHV-0223 For Phase III In Anxiety

Glutamate modulators could play a role in a range of central nervous system disorders, including social anxiety, amyotrophic lateral sclerosis. Biohaven's first – a reformulation of a generic ALS drug – could be on the market in two years.